Oric Pharmaceuticals (ORIC) investor relations material

Company overview and lead programs

• Focused on overcoming resistance in cancer with two late-stage programs: rinzimetostat (PRC2 inhibitor for prostate cancer) and enozertinib (brain-penetrant TKI for lung cancer targeting EGFR mutations).

• Rinzimetostat is in phase III (Himalayas-1) for castration-resistant prostate cancer post-abiraterone.

• Enozertinib is advancing toward phase III, with a significant data update expected at ESMO in Madrid soon.

• Company is well-funded, with a cash runway into the second half of 2028, covering planned phase III trials.

Rinzimetostat program and competitive landscape

• Rinzimetostat is differentiated by a 20-hour half-life, once-daily dosing, and improved safety profile versus competitors.

• Pfizer’s MEVPRO-1 phase III readout is expected in Q4; statistical analysis suggests a huge miss is unlikely, narrowing outcome scenarios.

• Rinzimetostat combines with darolutamide, the best-tolerated AR inhibitor, unlike Pfizer’s enzalutamide combination.

• Safety is expected to be the primary differentiator, with efficacy anticipated to be similar if target coverage is achieved.

• Himalayas-1 trial design closely mirrors MEVPRO-1, with a key difference being a cap on control arm treatment types.

Future development plans

• Planning additional trials in prostate cancer, including post-AR inhibitor and castration-sensitive settings.

• Next phase III (Himalayas-2) is targeted to start next year.

• Program update for rinzimetostat expected in the second half of the year, potentially covering trial progress or new data.